Clinical trials
Relapsed/Refractory Large B-Cell Lymphoma clinical trials
Below are recruiting relapsed/refractory large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 110 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT05908409RecruitingPhase 1/Phase 2
Testing an investigational drug for blood cancers that came back
This Phase 1/2 trial tests IDP-121 in people with certain blood cancers that have returned or did not respond to available treatments. The goal is to find a safe dose and see whether the treatment can help control the cancer.
Santander, CantabriaAges 18 years+ - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT06045910RecruitingPhase 1/Phase 2
A study of ALETA-001 for certain B-cell blood cancers
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
BirminghamAges 16 years+ - NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85 - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT06149286RecruitingPhase 3
Testing a new drug combo for follicular and marginal zone lymphoma
This trial is testing if a new drug called odronextamab combined with lenalidomide works better than the standard treatment (rituximab with lenalidomide) for adults with follicular lymphoma or marginal zone lymphoma that has come back or stopped responding to previous therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B-cell cancers
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Calgary, AlbertaAges 1 year+ - NCT06313957RecruitingPhase 1
Study of LUCAR-20SP for relapsed B-cell lymphoma
This trial tests a new treatment called LUCAR-20SP for people with certain types of B-cell lymphoma that have come back or not responded to prior therapy. The drug is a type of CAR-T therapy that targets the CD20 protein on lymphoma cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06365671RecruitingPhase 2
CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
ShanghaiAges 18 years+ - NCT06375161RecruitingEarly Phase 1
CAR-T cells for relapsed B-cell cancers
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Shanghai, Shanghai MunicipalityAges 4 months–1.3 years - NCT06393738RecruitingPhase 1
Study of ARV-393 for advanced non-Hodgkin lymphoma
This trial tests an experimental drug called ARV-393 for people with non-Hodgkin lymphoma that has come back or stopped responding to at least two previous treatments. The study aims to find out if the drug is safe and how well it works.
New Haven, ConnecticutAges 18 years+ - NCT06414148RecruitingPhase 2
Epcoritamab with or without lenalidomide and rituximab after CAR T
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Camperdown, New South WalesAges 16 years+ - NCT06446128RecruitingEarly Phase 1
CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06521255RecruitingPhase 3
New drug combo vs standard for relapsed DLBCL
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
BeijingAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+
Hear when a new Relapsed/Refractory Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed/refractory large b-cell lymphoma?
- Yes. Clin2 currently lists 110 recruiting relapsed/refractory large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed/refractory large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed/refractory large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed or Refractory B-cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.